Obecabtagene autoleucel for B-cell ALL in remission
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 40 or older (or 30-39 with serious health problems that make standard chemotherapy too risky).
- Your leukemia must be in complete remission after initial treatment, with no signs of cancer cells in the bone marrow.
- You need to have a protein called CD19 on your leukemia cells.
- You cannot have active leukemia in the fluid around your brain or spinal cord.
- Your liver, kidneys, lungs, and heart must be working reasonably well, and you should be able to manage daily activities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
This trial tests a new CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell acute lymphoblastic leukemia who have achieved their first complete remission after standard chemotherapy. The goal is to see if this therapy can keep the leukemia from coming back.
This early-phase study tests a personalized immune-cell treatment (CAR T) for adults with B-cell acute lymphoblastic leukemia (ALL) who still have tiny amounts of cancer detectable by a special test called MRD. It aims to improve outcomes for people who are in first remission but not completely “cancer-free” by MRD testing.
This trial tests a new drug called BEBT-908 combined with chemotherapy for adults with a specific type of acute lymphoblastic leukemia (ALL) who are in remission but still have small amounts of cancer cells (MRD positive). The goal is to see if this combination can get rid of those remaining cells and reduce the risk of relapse.
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
This trial tests a new CAR T-cell therapy (obecabtagene autoleucel) given as a consolidation treatment after initial remission to prevent relapse in people with high-risk B-cell ALL. It's for patients who have achieved first remission but still have high-risk features in their leukemia.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.